Table 2.
HbA1c and body weight over time according to CKD status during 12 months of treatment with semaglutide.
| Patients according to CKD status (n = 486) | Baseline | 6 months | P value* | 12 months | P value† | P value‡ |
|---|---|---|---|---|---|---|
| No/low CKD risk (n = 296) | ||||||
| HbA1c, % | 8.30 (1.90) | 6.70 (1.08) | <0.001 | 6.59 (0.98) | <0.001 | 0.016 |
| Body weight, kg | 98.9 (19.3) | 92.7 (18.2) | <0.001 | 91.5 (16.2) | <0.001 | <0.001 |
| CKD (n = 190) | ||||||
| HbA1c, % | 8.75 (1.79) | 7.09 (1.14) | <0.001 | 6.83 (0.91) | <0.001 | 0.002 |
| Body weight, kg | 98.5 (16.7) | 93.2 (15.9) | <0.001 | 92.6 (16.2) | <0.001 | <0.001 |
| Moderate risk CKD (n = 82) | ||||||
| HbA1c, % | 8.94 (1.68) | 7.12 (1.17) | <0.001 | 6.90 (0.92) | <0.001 | 0.075 |
| Body weight, kg | 100.4 (17.5) | 95.2 (16.6) | <0.001 | 94.0 (16.0) | <0.001 | 0.003 |
| High risk CKD (n = 53) | ||||||
| HbA1c, % | 8.34 (1.55) | 6.95 (0.97) | <0.001 | 6.66 (1.01) | <0.001 | 0.024 |
| Body weight, kg | 97.3 (15.4) | 90.8 (14.6) | <0.001 | 92.2 (14.8) | <0.001 | 0.139 |
| Very high risk CKD (n = 45) | ||||||
| HbA1c, % | 8.68 (1.97) | 7.12 (1.26) | <0.001 | 6.85 (0.76) | <0.001 | 0.057 |
| Body weight, kg | 96.5 (16.9) | 92.0 (16.4) | <0.001 | 92.1 (17.8) | <0.001 | 0.015 |
A total of 10 patients who were classified in the group of high/very high CKD risk because their baseline eGFR values were <45 mL/min/1.73 m2 did not have their baseline UACR assessed, and so they could not be further stratified as being of high or very high CKD risk. *6 months vs. baseline. †12 months vs. baseline. ‡6 months vs. 12 months. Results are expressed as mean (SD). The one-tailed paired t test was used to perform the comparisons.
CKD, chronic kidney disease; HbA1c, glycosylated hemoglobin; SD, standard deviation.